Showing 692 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Lenacapavir May Be Beneficial for Individuals Infected With HIV-2

Editor's pick
Infectious Disease Advisor
29 January 2024
New & experimental HIV treatments

Calibr announces license agreement with Gilead to develop a long-acting HIV antiviral agent for treatment in combination with lenacapavir

Editor's pick
EurekAlert!
8 January 2024
New & experimental HIV treatments

Trogarzo [Ibalizumab] Label Updated With 90-Second IV Push Loading Dose

Editor's pick
Infectious Disease Advisor
20 December 2023
Treatment simplification strategies

DTG/3TC vs TDF/FTC dual therapy: ALTAR study results too limited and too early to comment

Editor's pick
i-Base
6 December 2023
People with limited treatment options

Intramuscular Administration of HIV Treatment Ibalizumab Compared With IV Infusion

Editor's pick
Monthly Prescribing Reference
17 October 2023
Pharmaceutical industry

People with HIV offered hope of self-injected drug at home

Editor's pick
The Guardian
3 October 2023
Injectable & long-acting HIV treatment

Could this new hydrogel make HIV therapy more convenient?

Editor's pick
EurekAlert!
28 September 2023
Access to healthcare

Open Letter: Community Statement on Accelerating Access to Lenacapavir by Gilead

Editor's pick
AfroCAB
18 July 2023
Injectable & long-acting HIV treatment

Study of Weekly Oral HIV Treatment Resumes

Editor's pick
POZ
8 May 2023
New & experimental HIV treatments

Merck reveals HIV combo trial is back in the running after FDA partial hold lifted 

Editor's pick
FierceBiotech
27 April 2023
New & experimental HIV treatments

GSK drops one of 2 maturation inhibitors in HIV pipeline

Editor's pick
FierceBiotech
27 April 2023
New & experimental HIV treatments

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Editor's pick
Merck press release
23 February 2023
HIV treatment for children & young people

European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

Editor's pick
Gilead Sciences press release
29 November 2022
Injectable & long-acting HIV treatment

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

Editor's pick
POZ
10 November 2022
HIV treatment

IDWeek 2022 Study Bites: What’s New in HIV Antiretroviral Therapy

Editor's pick
TheBodyPro
10 November 2022
Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
Antibody-based treatment

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Editor's pick
ViiV press release
26 October 2022
People with limited treatment options

Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience

Editor's pick
NATAP
26 October 2022
The search for a cure

Danish-led study takes major step in pursuit of HIV cure

Editor's pick
EurekAlert
18 October 2022
New & experimental HIV treatments

5 FDA decisions to watch in the fourth quarter

Editor's pick
BioPharma Dive
3 October 2022
Pharmaceutical industry

Under new leadership, CytoDyn ditches COVID-19 programs

Editor's pick
FierceBiotech
30 September 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
Injectable & long-acting HIV treatment

Long-Acting Injectable HIV Therapy for People Who Won’t Take ART?

Editor's pick
NEJM Journal Watch
10 August 2022
New & experimental HIV treatments

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

Editor's pick
Gilead Sciences press release
28 July 2022